 CULVER CITY, Calif. EL SEGUNDO, Calif.--BUSINESS WIRE--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. NASDAQ: NK, a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. Together, ImmunityBio and NantKwest will have a broad, clinical-stage p 